The Lynx Group
Cholangiocarcinoma News

CCA Summit 2020 Highlights

December 2020, Vol 1, No 3 — January 5, 2021
The recent FDA approval of the first FGFR inhibitor, pemigatinib (Pemazyre), and the positive results from the phase 3 study of the first IDH1 inhibitor, ivosidenib (Tibsovo), represent major breakthroughs in the treatment of patients with cholangiocarcinoma (CCA), a rare cancer associated with poor outcomes. However, the duration of response with these agents is still relatively short.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
The current standard of care for the systemic treatment of patients with advanced gallbladder cancer is the chemotherapy combination of gemcitabine and cisplatin, which is suboptimal, yielding only modest benefit, said Richard Kim, MD, Section Chief, Gastrointestinal Medical Oncology, Moffitt Cancer Center, Tampa, FL, at the 2020 Cholangiocarcinoma Summit.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).
Read More

December 2020, Vol 1, No 3 — January 5, 2021
New cytotoxic chemotherapy regimens and novel combinations are being evaluated in clinical trials in an effort to improve the outcomes of chemotherapy in the adjuvant and palliative settings in patients with biliary tract cancer, including cholangiocarcinoma (CCA), said Angela Lamarca, MD, PhD, MSc, Consultant, Medical Oncology, the Christie NHS Foundation Trust, Manchester, United Kingdom. She discussed the future of cytotoxic chemotherapy for this patient population at the 2020 Cholangiocarcinoma Summit.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
Liver transplant is emerging as a treatment option in patients with unresectable hilar or intrahepatic cholangiocarcinoma (CCA), with accumulating data supporting transplant protocols in patients with early-stage CCA.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
Despite the onslaught of the COVID-19 pandemic, researchers are hard at work to develop innovative therapies that will make a difference in the lives of patients with cancer.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
At the 2020 Cholangiocarcinoma Summit, Nabeel El-Bardeesy, PhD, Associate Professor, Medicine, Harvard Medical School, and Associate Geneticist, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, moderated a session titled “Molecular Biomarkers in CCA: Focus on Current and Emerging Technologies.” The session focused on how best to integrate the array of genomic testing platforms into clinical practice. The session included 2 presenters who discussed this topic.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
Patients with relapsed or refractory HER2-amplified biliary tract cancer have few treatment options after first-line therapy. Shubham Pant, MD, Associate Professor, Gastrointestinal Oncology, M.D. Anderson Cancer Center, Houston, TX, presented the results of a phase 1 clinical trial he and his colleagues conducted. The study examined the safety and antitumor activity of zanidatamab, a bispecific (ie, binding to 2 distinct sites on the HER2 receptor) HER2-targeted antibody. The unique antibody geometry of zanidatamab enables it to activate several mechanisms of action after binding to the HER2 receptor.
Read More

December 2020, Vol 1, No 3 — January 5, 2021
At diagnosis, the majority of patients with intrahepatic cholangiocarcinoma (CCA) present with advanced disease and a poor prognosis. Comprehensive genomic profiling (CGP) of intrahepatic CCA has revealed multiple potential therapeutic targets, including FGFR2, ERBB2 (HER2), and IDH1. Therefore, performing CGP early in the disease course is critical to increasing first-line clinical trial enrollment and access to treatment with FGFR inhibitors.
Read More

Page 1 of 2

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: